Processing...
All Trials
Search
Search
There are 1652 active trials in our database.
Click on a trial to see more information.
1652 trials meet filter criteria.
Sort by:
Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors
TrialFetch AI summary: Enrolling children, adolescents, and young adults (1–≤30 years) with recurrent/refractory solid or CNS tumors lacking curative options, including those previously exposed to irinotecan/temozolomide if not refractory. Patients receive a flavored oral irinotecan formulation (VAL-413, prodrug converted to SN-38 topoisomerase I inhibitor) plus oral temozolomide in 5-day, 21-day cycles, with a cycle 1 PK comparison dose of orally administered IV irinotecan solution.
ClinicalTrials.gov ID: NCT04337177
TrialFetch AI summary: Relapsed/refractory pediatric and young adult sarcomas (osteosarcoma, Ewing, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue; ages 2–40) receive gemcitabine/docetaxel plus off‑the‑shelf, ex vivo expanded TGFβ‑imprinted universal donor NK cells designed to resist TGFβ-mediated suppression in the tumor microenvironment. NK infusions are given on day 12 of 21‑day cycles (up to 6 NK doses within 8 chemotherapy cycles) with safety and 6‑month PFS assessed.
ClinicalTrials.gov ID: NCT05634369
TrialFetch AI summary: Enrolling adults with ECOG 0–1 who have selected relapsed/refractory cancers: solid tumors (e.g., post–docetaxel/AR-targeted mCRPC or metastatic/unresectable NUT carcinoma) and hematologic malignancies including CMML and intermediate/high-risk myelofibrosis after JAK inhibitor; stable treated brain mets allowed. Investigational therapy is EP31670 (NEO2734), an oral first-in-class dual BET and CBP/p300 inhibitor given intermittently as monotherapy (solid tumors/CMML) or combined with ruxolitinib or momelotinib in myelofibrosis.
ClinicalTrials.gov ID: NCT05488548
TrialFetch AI summary: Adults with CLDN18.2-positive, unresectable locally advanced or metastatic gastric/GEJ or pancreatic adenocarcinoma, ECOG 0–1. Tests the CLDN18.2×CD3 bispecific T‑cell engager ASP2138 as monotherapy and combined with pembrolizumab+mFOLFOX6 (first-line HER2‑negative gastric/GEJ), ramucirumab+paclitaxel (second-line gastric/GEJ), or mFOLFIRINOX (first-line pancreatic).
ClinicalTrials.gov ID: NCT05365581
TrialFetch AI summary: For patients ≥12 years with unresectable/metastatic fibrolamellar hepatocellular carcinoma or adults with other solid tumors harboring the DNAJB1‑PRKACA fusion, including checkpoint‑naïve and some checkpoint‑experienced FLC cohorts. Treatment combines an off‑the‑shelf DNAJB1‑PRKACA junction neoepitope peptide vaccine (adjuvanted with TLR1/2 agonist XS15) with nivolumab (PD‑1 inhibitor) and ipilimumab (CTLA‑4 inhibitor) to augment vaccine‑primed T‑cell responses; a re‑enrollment option may use nivolumab plus vaccine if prior CTLA‑4 toxicity.
ClinicalTrials.gov ID: NCT04248569
TrialFetch AI summary: Pediatric and young adult patients (1–21 years) with relapsed/refractory, AFP-high (≥100 ng/mL), HLA-A2–positive hepatoblastoma, HCN-NOS, or HCC receive a single infusion of autologous ET140203 T cells after lymphodepletion. ET140203 (JWATM-203) is an engineered T-cell therapy using an ARTEMIS receptor with a TCR-mimic that targets AFP158–166/HLA-A*02:01 to selectively kill AFP+/HLA-A2+ liver cancer cells.
ClinicalTrials.gov ID: NCT04634357
TrialFetch AI summary: Adults with advanced or recurrent solid tumors lacking standard options receive BP1001-A, a neutral-charge liposomal antisense oligonucleotide targeting GRB2 to inhibit RAS/MAPK and PI3K/AKT signaling; the expansion cohort enrolls recurrent/persistent epithelial ovarian, primary peritoneal, fallopian tube, or endometrial cancers for BP1001-A combined with standard-dose paclitaxel. Key exclusions include CNS disease, significant recent cardiovascular events, inability to receive paclitaxel, and strong CYP3A4/2C8 modulators.
ClinicalTrials.gov ID: NCT04196257
TrialFetch AI summary: Adults with metastatic uveal melanoma after at least one prior systemic or liver-directed therapy (ECOG 0–1) receive a single IV dose of 225Ac-MTI-201, an MC1R-targeted peptide radioligand delivering alpha-particle radiation, in a dose-escalation design. Key exclusions include prior alpha therapy, significant immunodeficiency or uncontrolled comorbidities, substantial prior marrow irradiation, pregnancy, and untreated/unstable CNS metastases.
ClinicalTrials.gov ID: NCT05496686
TrialFetch AI summary: Adults with measurable, biopsy-accessible stage III (macroscopic nodal) or stage IV melanoma, ECOG 0–1, and no prior PD‑1/PD‑L1 or CTLA‑4 therapy receive ipilimumab plus nivolumab combined with CBL0137, a non-genotoxic DNA intercalator that traps FACT to activate p53 and suppress NF‑κB/HSF1/MYC. Excludes active autoimmune disease or need for immunosuppression; serial biopsies and blood draws required.
ClinicalTrials.gov ID: NCT05498792
TrialFetch AI summary: Eligible patients are adult women with relapsed/refractory locally advanced or metastatic breast cancer (ECOG 0–1) who have progressed after standard therapies or lack standard options; a dose-expansion cohort is restricted to measurable triple-negative disease (ER/PR <10%, HER2-negative) previously treated with at least one active TNBC regimen and with a biopsiable lesion. All participants receive oral OTS167PO, an investigational small-molecule inhibitor of maternal embryonic leucine zipper kinase (MELK), in single-arm dose escalation to define MTD with PK/safety characterization and TNBC expansion at the selected dose.
ClinicalTrials.gov ID: NCT02926690